The U.S. Food and Drug Administration (FDA) announced Wednesday that it has received a letter of commitment from Zoetis Animal Health that, by this coming fall, the company will suspend the sale of Histostat (nitarsone) and formally request that FDA withdraw approval for the drug by the end of the year.

For more of this story, click here.